The introduction of novel androgen receptor (AR) antagonists for clinical treatment has improved outcomes; however, most metastatic castration-resistant prostate cancer (mCRPC) patients ultimately develop resistance to these therapies. This evidence concerns the gene AR and Familial prostate cancer.